ICER's pricing model ranges from $10 to $52,880
Infectious diseae prevention could completely reshape how and where American healthcare is delivered.
Healthcare executives in all sectors are beginning to think about how the economic consequences of COVID-19 are going to affect their organizations and lines of business.
Trauma was the big ticket hospital admission pre-Covid-19.
Novel drugs, value-based contracting, biosimilars, and regulatory activity addressing costs will be among the hot button issues in the coming year.
New study shows that although costly, more effective treatments increase survival rates in Medicare patients.
A new cost analysis study presented at Psych Congress 2018, highlights the substantial economic burden among U.S. veterans with treatment-resistant depression and what can be done about it.
The economic impact of an Ebola pandemic could reach $32 billion by 2015, according to the World Bank, while costs to the healthcare insurance industry will depend on how quickly the disease is controlled in countries with high insurance penetration, according to the Insurance Information Institute (III).
A Cornell study finds that the true cost of cancer drugs is 30% less than a decade ago, once longevity and quality of life are considered.